February 21, 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Andrew J. MacDougall to the board of directors, effective immediately, in order to satisfy the statutory requirement for resident Canadians to comprise at least 25% of the board of directors pending completion of the board’s director nomination process.
“The board is taking a thoughtful and considered approach to the addition of a new board member through a comprehensive evaluation process” said Mario Gobbo, Chairman of the Board. “Mr. MacDougall’s interim service on the board will provide us with time to complete our evaluation and we thank him for his
contribution through this period”.
Following the appointment of Mr. MacDougall, the board is comprised of seven directors, five of whom are independent of Helix. The board of directors also appointed Dr. Marek Orlowski to the audit committee of the board in place of Mr. John Rogers, who resigned as a director effective February 8, 2013.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
Helix BioPharma Corp.
Tel: 905 841-2300